Nama's AI scorecard currently rates Immatics Sell (1.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does IMTX report earnings?

Immatics's next scheduled report is on Nov 17, 2026. Analysts expect EPS of -$0.50.

What is the IMTX price target?

The median analyst price target from 7 analysts is $16.00, with a range of $11.80 – $21.00.

Is IMTX Shariah compliant?

Nama's AAOIFI-style screen reads Immatics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Immatics (IMTX)

Healthcare · Biotechnology · NASDAQ

Immatics (IMTX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.05B and a free-cash-flow yield of -24.3%. Over the most recent reported fiscal year, revenue declined 69.0%. Nama's AI scorecard rates it Sell, 1.8 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 1.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Lagging · -19.3% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-54.6%

How far the last close sits under the highest price of the past five years.

Market cap	$1.05B
Trailing P/E	—
Price / book	2.1
Price / sales	22.3
FCF yield	-24.3%
Dividend yield	—
Gross margin	0.0%
Operating margin	-735.0%
Net margin	0.0%
Revenue growth (YoY)	-69.0%
Revenue growth (3-yr annual)	-34.6%
EPS growth (YoY)	-1353.3%
FCF/share growth (YoY)	—
Beta	1.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

IMTX earnings

Next report: Nov 17, 2026 (Q3 2026, EPS estimate -$0.50). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 18, 2026	-$0.53	-$0.48	-10.4%	$10.25M
Q1 2026	May 12, 2026	-$0.51	-$0.44	-15.9%	$8.53M
Q4 2025	Mar 5, 2026	-$0.34	-$0.48	+29.2%	$22.15M
Q3 2025	Nov 17, 2025	-$0.49	-$0.45	-8.9%	$5.81M

IMTX analyst price target

Median target $16.00 from 7 analysts, ranging $11.80 – $21.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live IMTX data on Nama Insights →

IMTX FAQ

Is IMTX a buy?: Nama's AI scorecard currently rates Immatics Sell (1.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does IMTX report earnings?: Immatics's next scheduled report is on Nov 17, 2026. Analysts expect EPS of -$0.50.
What is the IMTX price target?: The median analyst price target from 7 analysts is $16.00, with a range of $11.80 – $21.00.
Is IMTX Shariah compliant?: Nama's AAOIFI-style screen reads Immatics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.